profit from every $100 of sales.
$0$100
Cullinan Therapeutics
$10.28+0.88% today
+24.3% in 1 year
1-year low $8.271-year high $22.95
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cullinan Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$220 million of profit last year.
SalesProfit
Cullinan Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cullinan Therapeutics | No profit yet | ||
 Atai Beckley N.V | No profit yet | ||
 Avalyn Pharma | No profit yet | ||
 High Tide | No profit yet | ||
 Satellos Bioscience | No profit yet |
AI analysis
An AI analyst reads Cullinan Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -132 | -191 | -197 | -242 | |
| -132 | -190 | -197 | -241 | |
| 111 | -153 | -167 | -220 | |
| 2.38 | -3.21 | -2.78 | -3.36 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 561 | 484 | 622 | 448 |
| Cash | 156 | 98 | 83 | 88 |
| Total debt | 5 | 4 | 2 | 3 |
| Total liabilities | 26 | 30 | 31 | 40 |
| 535 | 454 | 590 | 409 | |
| 47 | 42 | 54 | 59 | |
| -19.3% | -32.9% | -26.3% | -46.4% | |
| 20.8% | -33.8% | -28.4% | -53.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -127 | -134 | -145 | -176 | |
| 1 | 0 | – | 0 | |
| -128 | -134 | -145 | -176 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 28 | 30 | 38 | 36 |
Valuation
- –
- –
- –
- 2.7×
- –
- –
- –
- -26.3%
- -32.9%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -65.2%
- -22.0%
- -51.5%
- -54.9%
- -65.3%
- –
Growth
- –
- –
- −21.0%
- –
- +7.5%
Financial health
- 0.3×
- 0.01
- 0.6%
- –
- 10.28
- 10.28
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 963
Bottom 20%of 894
Bottom 2%of 991
What analysts expect
- Average price target
- $31.14
- Range
- $26.00 – $38.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.75 | -0.84 | +10.3% |
| Mar 10, 2026 | -0.77 | -0.80 | +3.8% |
| Nov 6, 2025 | -0.77 | -0.95 | +18.9% |
| Aug 7, 2025 | -1.07 | -0.83 | −28.9% |
| May 8, 2025 | -0.74 | -0.78 | +5.1% |
| Feb 27, 2025 | -0.73 | -0.75 | +2.7% |
| Nov 7, 2024 | -0.69 | -0.78 | +11.5% |
| Aug 8, 2024 | -0.75 | -0.73 | −2.7% |
News
Cullinan Therapeutics reports Q3 resultsSeeking Alpha · Nov 10, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
45No pass
Philip Fisher
32No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
24No pass
Questions about Cullinan Therapeutics
Is Cullinan Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cullinan Therapeutics AI analysis
What does Cullinan Therapeutics do?
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. It is in Medical - Pharmaceuticals.
Does Cullinan Therapeutics pay a dividend?
No. Cullinan Therapeutics does not pay a dividend at the moment.
Is Cullinan Therapeutics stock halal?
Questionable. Cullinan Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Cullinan Therapeutics stock done over the past year?
Up 24.3% over the past twelve months, to $10.28. It traded between $8.27 and $22.95 and is 55.2% below its high.
Who are Cullinan Therapeutics's competitors?
The largest listed companies in the same industry are Atai Beckley N.V, Avalyn Pharma, High Tide and Satellos Bioscience. The peers table on this page compares their profit, growth and price with Cullinan Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.